Activist Investor Jorey Chernett Demands Strategic Review, Sale of TMS Business
Summary
Activist investor Jorey Chernett, holding a 14.12% stake in Neuronetics, has formally demanded the Board initiate a comprehensive review of strategic alternatives, including the potential sale of its transcranial magnetic stimulation (TMS) business, to unlock shareholder value.
Key Events
-
Formal Demand for Strategic Review
Jorey Chernett, holding 14.12% of outstanding shares, sent a letter to the Board demanding an immediate, comprehensive review of strategic alternatives.
-
Call for TMS Business Sale
The letter specifically urges the evaluation of selling the transcranial magnetic stimulation (TMS) business, arguing it would unlock substantial shareholder value.
-
Proposed Value Creation
Chernett suggests a TMS sale could enable a special dividend (approximating current market cap), full debt retirement, and establish over $100 million in cash for the remaining clinic business.
-
Valuation Disconnect Cited
The activist highlights a significant undervaluation of Neuronetics' assets, providing comparative valuations for both its TMS and clinic businesses.
Analysis
Jorey Chernett, Neuronetics' largest independent shareholder with a 14.12% stake, has formally escalated his engagement by requesting the Board initiate a comprehensive review of strategic alternatives. The letter specifically urges the evaluation of selling the transcranial magnetic stimulation (TMS) business, arguing that the company's current structure prevents it from maximizing shareholder value. Chernett highlights a "massive valuation disconnect" compared to peers and proposes that a TMS sale could generate a special dividend, retire debt, and provide over $100 million in cash, enabling the company to focus on its clinic business. This move puts significant pressure on the Board to address shareholder concerns and could lead to a major restructuring or sale of assets, potentially impacting the company's long-term strategic direction and valuation.
At the time of this filing, STIM was trading at $1.66 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $109.5M. The 52-week trading range was $0.80 to $4.85. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.